Exact Sciences Schedules Second Quarter 2024 Earnings Call

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S.

BusinesswireJul 8 06:00 ET

People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. -- WSJ

By Chip Cutter You are likely not getting a big promotion this year. So how about a job swap? Many workers say they are considering that question as they feel stuck in their roles. With the white-co

WSJJul 7 05:30 ET

Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group

Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group

Dow JonesJul 2 11:32 ET

Exact Sciences Is Maintained at Outperform by Evercore ISI Group

Exact Sciences Is Maintained at Outperform by Evercore ISI Group

Dow JonesJul 2 11:32 ET

Exact Sciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 67.42% Evercore ISI Group $80 → $72 Maintains Outperform 06/27/2024 62.77% BTIG $80 → $70 Maint

BenzingaJul 2 11:18 ET

Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72

Evercore analyst Vijay Kumar maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $90 to $72.According to TipRanks data, the analyst has a success rate of 47.4% and

Moomoo NewsJul 2 08:33 ET · Ratings